ZA200509945B - Methods for the diagnosis and prognosis of Alzheimer's disease - Google Patents
Methods for the diagnosis and prognosis of Alzheimer's disease Download PDFInfo
- Publication number
- ZA200509945B ZA200509945B ZA200509945A ZA200509945A ZA200509945B ZA 200509945 B ZA200509945 B ZA 200509945B ZA 200509945 A ZA200509945 A ZA 200509945A ZA 200509945 A ZA200509945 A ZA 200509945A ZA 200509945 B ZA200509945 B ZA 200509945B
- Authority
- ZA
- South Africa
- Prior art keywords
- disease
- polymorphism
- alzheimer
- minor allele
- individual
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 84
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 68
- 238000004393 prognosis Methods 0.000 title claims description 16
- 238000003745 diagnosis Methods 0.000 title claims description 14
- 108020004414 DNA Proteins 0.000 claims description 58
- 108700028369 Alleles Proteins 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 39
- 241001465754 Metazoa Species 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 101150033922 ABCA2 gene Proteins 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 28
- 210000000130 stem cell Anatomy 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 21
- 238000003752 polymerase chain reaction Methods 0.000 claims description 20
- 230000009261 transgenic effect Effects 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 17
- 101000801645 Homo sapiens ATP-binding cassette sub-family A member 2 Proteins 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 230000001747 exhibiting effect Effects 0.000 claims description 15
- 102100033618 ATP-binding cassette sub-family A member 2 Human genes 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 238000002105 Southern blotting Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 101710163270 Nuclease Proteins 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 229940126601 medicinal product Drugs 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 2
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 2
- 101100161485 Homo sapiens ABCA2 gene Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000011543 agarose gel Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 231100000640 hair analysis Toxicity 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 11
- 241001529936 Murinae Species 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108700019146 Transgenes Proteins 0.000 description 8
- 238000012216 screening Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 101150071577 chi2 gene Proteins 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001109 blastomere Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 3
- 102000056779 human ABCA2 Human genes 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100022033 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102100022036 Presenilin-2 Human genes 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 101150031224 app gene Proteins 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IZAOBRWCUGOKNH-OAHLLOKOSA-N 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](C)C=1C(=CC(F)=CC=1)CCCC(O)=O)C1=CC(F)=CC=C1F IZAOBRWCUGOKNH-OAHLLOKOSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000251204 Chimaeridae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800001442 Peptide pr Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
® ® WO 2004/113568 , PCT/FR2004/001509
METHODS FOR DETECTING ALZHEIMER'S DISEASE
The present invention relates to methods for the diagnosis or for the prognosis of Alzheimer’s disease.
It also relates to the kits for the diagnosis or for the prognosis of Alzheimer’s disease.
Alzheimer’s disease is a neurodegenerative disease which affects a large proportion of the elderly population. In clinical terms, this disease is characterized by a loss of cognitive functions and, in neuropathological terms, it is characterized by the presence in the brain of intracellular neurofibrillar deposits and of extracellular deposits of the P-amyloid (AB) peptide forming amyloid plaques. Amyloid plaques are mainly composed of AP peptides containing 40 or 42 amino acids, which are generated by a process of proteolysis of the P-amyloid peptide precursor protein (APP). Extracellular deposits of AP are specific for
Alzheimer's disease. They represent the early and invariable characteristic of all forms of Alzheimer’s disease, including the familial forms.
The familial forms of the disease appear relatively early (between 40 and 60 years old). They appear to be due, at least in part, to mutations in the APP gene and in the presenilin-1 (PS1l) and presenilin-2 (PS2) genes.
Mutations in these three genes induce changes in the proteolysis of APP, leading to an overproduction of AB and to the early appearance of the pathology and of the symptoms, which are similar to those of the sporadic forms of Alzheimer’s disease.
A connection between cholesterol and Alzheimer’s disease has also been established from epidemiological studies and from results of recent biochemical and cell biology studies (see review Hartmann, T. (2001) TINS 24: S45-48). A high cholesterol level at adult age, and
(1) @® also a high arterial blood pressure, significantly increase the risk of Alzheimer’s disease (Kivipelto et al., 2001 Br Med J. 322 : 1447).
On the other hand, a very reduced risk is recorded in populations being treated with cholesterol-lowering agents of the statin type (Wolozin et al. (2000) Arch
Neurol. 57 : 1439; Jick et al. (2000) Lancet 356 : 1627).
The molecular link appears to have been recently established. In vitro and in vivo, a high cholesterol level increases production of the AB peptide and accelerates the appearance of amyloid plaques (Sparks et al. (1994) Exp. Neurol. 126 : 88-94; Refolo et al. (2000) Neurobiol. Dis. 7 : 321-331; Puglielli et al. (2001) Nat. Cell Biol. 3 : 905; Shie et al. (2002).
Neuroreport 13 : 455), whereas inhibitors of the pathway for cholesterol synthesis decrease them (Simons et al. (1998) PNAS USA 95: 6460-6464; Fassbender et al. (2001) PNAS USA 98 : 5856, Refolo et al., (2001)
Neurobiol. Dis. 8 : 890-899).
Despite significant advances, the medical community is still confronted with a lack of molecules which are really effective against Alzheimer's disease. One of the reasons for this lack of molecules lies in the difficulty in finding targets for effective screening of molecules capable of exerting a therapeutic action against this disease.
Furthermore, early detection of this disease appears to be determinant, in order to provide treatment before the first symptoms, which are highly disabling to the patients, begin to manifest themselves.
In addition, due to the varied forms of this disease, it appears to be necessary to target the treatment as a function, firstly, of the individuals to be treated
® @ and, secondly, of the molecule which can be used for the treatment. This pharmacogenomic or pharmacogenetic approach appears to be increasingly important.
The ABCA2 protein is a protein belonging to the large family of ABC (ATP-binding cassette) type cholesterol i transporters. This transporter is expressed specifically in the brain.
The cloning of the ABCA2 gene was described in 2000 by
Zhao et al. (Biochem. J., 350, 865-872). The sequence was also the subject of PCT application WO 01/14414, deposited by the company ACTIVEPASS PHARMACEUTICALS.
Various hypotheses are put forward in that application, regarding the role of ABCA2, but without there being any result to support them.
Various polymorphisms of the ABCA2 gene have already been identified. Their sequences are in particular accessible in the dbSNP database of the NCBI. Among the various polymorphisms listed in this base, the polymorphism rs908832 is described.
This polymorphism is characterized by a major allele in the Caucasian population, which is a guanine located at position 348 on the sequence SEQ ID No. 2, and a minor allele in the Caucasian population, which is an adenine located at position 348 on the sequence SEQ ID No. 1.
Alternatively, this mononucleotide polymorphism is represented by the sequences SEQ ID No. 3 and SEQ ID
No. 4 which are partially complementary to SEQ ID No. 1 and SEQ ID No. 2, respectively. This polymorphism is then characterized by a major allele in the Caucasian population, which is a cytosine located in position 201 on the sequence SEQ ID No. 4, and a minor allele in the
Caucasian population, which is a thymidine located at position 201 on the sequence SEQ ID No. 3.
® o This polymorphism is synonymous, i.e. it does not modify the sequence of the translated protein. The two alleles of the polymorphism are part of codons which encode an aspartic acid. This coding polymorphism is located on exon 14 of the transcript exhibiting the sequence SEQ ID No. 5 at position 2185.
Surprisingly, the applicant has shown that individuals exhibiting the minor allele of the rs908832 polymorphism of the ABCA2 gene have an increased risk of early development of Alzheimer’s disease.
This discovery is particularly important since it provides, to the applicant’s knowledge, for the first time, proof of a link between the ABCA2 protein, and in particular a polymorphism of the gene encoding this protein, and a pathological state, such as Alzheimer’s disease.
It makes it possible to confirm and/or to give a prognosis for the severity of the affliction in patients for whom Alzheimer’s disease has already been diagnosed, and also the probable effectiveness of the treatments envisioned, or else to give a prognosis for the risks of appearance of the disease in individuals not exhibiting symptoms of Alzheimer’s disease, including individuals related to patients for whom the diagnosis has been confirmed.
It also makes it possible to confirm a major functional role for ABCA2 in the physiopathology of Alzheimer’s disease, justifying the use of tests to screen for molecules capable of exerting a stimulatory or inhibitory action on the activity of ABCA2 for the purpose of a therapeutic application against
Alzheimer's disease.
A first subject of the present invention is thus a method for the diagnosis or for the prognosis of
- 5 = ® ® Alzheimer’s disease in an individual. Said method comprises at least one step of detection of the alleles of a polymorphism of the ABCA2 gene. Advantageously. such a polymorphism is a polymorphism involved in
S Alzheimer’s disease. It is preferably the rs908832 polymorphism, but it may be any other polymorphism in genetic linkage disequilibrium with the rs908832 polymorphism.
Suitable individuals may, for example, be: - individuals who do not exhibit the symptoms of
Alzheimer's disease, - individuals in whom the risk of developing
Alzheimer’s disease has already been detected, but who do not yet exhibit the symptoms of the disease, and - individuals who have previously been diagnosed as suffering from Alzheimer’s disease, for whom a confirmation of the diagnosis is desired.
The step or steps of detection (which may or may not be simultaneous) of the presence or absence of the minor allele of the rs908832 polymorphism are carried out directly or indirectly by any suitable means using biological samples.
The present invention therefore also relates to a method for screening biological samples taken from individuals, in particular individuals not exhibiting symptoms of Alzheimer’s disease, in order to detect individuals highly liable to develop Alzheimer’s disease. Such a screening comprises searching, possibly simultaneously, in said biological samples, for the presence of the minor allele of the rs908832 polymorphism.
Said samples containing the DNAs or the proteins to be identified may be of various origin. They may. for
[ ® example, be blood samples, sperm samples or hair samples (with the roots) or any other sample containing nucleated cells. Preferably, the biological samples analyzed are blood samples. In this case, the DNA to be identified is taken from the leukocytes.
For the purpose of the present invention, the term “biological sample” is intended to mean samples directly derived from the individual for whom a diagnosis or a prognosis is desired without any other transformation, or samples which have undergone one or more steps of preparation so as to conserve only a fraction thereof which is of use for the detection steps, for example a crude cell extract.
The techniques for detecting or identifying the presence or absence of the DNAs carrying the minor allele of the rs908832 polymorphism can be combinations of the techniques of Polymerase Chain Reaction (PCR), of hybridization, of Southern blotting, of digestion with nucleases, of Restriction Fragment Length
Polymorphism (RFLP) and/or of direct sequencing of the
PCR products. All these techniques are known to those skilled in the art.
In general, all the techniques for identifying the DNAs carrying the minor allele of the rs908832 polymorphism which can be used in the context of the present invention comprise a prior step of collecting the biological sample (s) containing the DNAS to be identified and a step of extraction of the genomic DNA according to the standard techniques well known to those skilled in the art, for example according to the method of Smith et al. (The Lancet, 1992, 339, pp. 1375-7).
Such a method of identification can comprise: a) extracting the DNA of said individual,
® ® b) amplifying said isolated DNA using primers capable of amplifying the sequences corresponding to each one of the alleles of the rs908832 polymorphism of the ABCA2 gene, and c) determining at least one of the alleles of the rs908832 polymorphism of the ABCA2 gene in the amplified DNA.
According to an advantageous embodiment, the PCR technique is used. Thus, step Db) advantageously comprises a polymerase chain reaction step. This technique consists first of all in synthesizing oligonucleotides complementary to the sequence of the regions which delimit the DNA segment to be amplified (primers) . These oligonucleotides serve as primers for the DNA polymerase. Then, the steps of heat- denaturation (92-95°C), in order to separate the two
DNA strands, of hybridization with the two specific primers by virtue of a decrease in temperature (50- 55°C) and of extension of the primers with a DNA polymerase at 70-72°C are carried out.
Such primers for amplifying each one of the alleles of the rs908832 polymorphism of the ABCA2 gene, and in particular of the minor allele, and also the sequences complementary thereto, constitute other subjects of the present application. Advantageously, they have respective sequences such that the number of bases between their respective points of hybridization on the
DNA molecule is between 25 and 2500 base pairs, and preferably between 100 and 500 base pairs.
Advantageously, such primers have between approximately 15 and 30 contiguous nucleotides of the sequence SEQ ID
No. 3 or of the sequence SEQ ID No. 4. Preferably, they are a pair of primers having the sequences SEQ ID No. 6 and SEQ ID No. 7.
® ® According to an advantageous embodiment, a subject of the present application is a method wherein the amplified DNA carrying the minor allele of the rs908832 polymorphism is distinguished from the amplified DNA not carrying this allele by specific hybridization of two probes, each one of them being specific for one of § the two forms of the polymorphism. These probes, and also the sequences complementary thereto, constitute other subjects of the present application.
Advantageously, these probes consist respectively of approximately 12 to 17 contiguous nucleotides of the sequence SEQ ID No. 3 or SEQ ID No. 4. Preferably, they have the sequences SEQ ID No. 8 and SEQ ID No. 09, respectively.
The amplified DNA carrying the minor allele of the rs908832 polymorphism can also be distinguished from the amplified DNA not carrying this allele by the technique using the 5° nuclease activity of DNA polymerase I (TagMan).
According to an advantageous embodiment, a subject of the present application 1s a method wherein the amplified DNA carrying the rs908832 polymorphism is distinguished from the amplified DNA not carrying this polymorphism by restriction fragment polymorphism (RFLP) analysis. Advantageously, the restriction fragments have been obtained by digestion of the amplified DNA with a restriction enzyme before migration in agarose gel, Southern blotting onto membrane and hybridization.
In order to obtain both greater sensitivity and better specificity, it is also possible to carry out two successive PCRs using two different pairs of primers (*nested PCR”): a first pair of external primers which makes it possible to obtain an amplified DNA fragment as in conventional PCR and a second pair of internal
® ® primers in order to amplify the DNA fragment obtained from the first PCR.
In order to determine the genetic footprint of the desired region, the DNA fragments obtained by PCR can also be separated by electrophoresis according to their . size and visualized with ETB (ethidium bromide) and ultraviolet rays.
A particularly advantageous possibility in the present case consists in carrying out a PCR with a first primer having at its 3’ end the mutated nucleotide sequence, and a second primer having at its 3’ end the wild-type nucleotide sequence. The difference in denaturation temperature in these two cases, and consequently in efficiency of amplification, makes it possible to distinguish the mutant DNA from the wild-type DNA.
According to another alternative, the amplified DNA fragments are directly identified by dot blot technique, which consists in depositing a sample of the
DNA fragments produced from the PCR onto a nylon filter, in denaturing the DNA fragments, in hybridizing them with a radioactive specific probe and in washing in order to eliminate the excess radioactive product not attached, and then in performing an autoradiogram.
The revealing can also be carried out by other means, using specific probes comprising a label other than a radioactive label, for example a dye or else a fluorescent label.
According to another alternative, it is also possible to detect the presence or absence of mutations in the
DNAs comprising the rs908832 polymorphism by direct sequencing of all or part of the amplified DNA fragments. Such a method consists in determining the nucleotide sequence at the rs908832 polymorphism. The sequencing can be carried out by any method known to
® @® those skilled in the art, for example by the Sanger method or else by the Maxam and Gilbert method.
According to another alternative, the detection of the presence or absence of the DNAs carrying the rs908832 polymorphism can be carried out using the Southern blotting technique, which consists in performing an electrophoresis of the DNA fragments obtained after treatment with one or more restriction enzymes. The gel is then denatured and blotting is carried out onto a nylon membrane. This membrane is intended to be hybridized with a specific probe. After washing to eliminate the excess radioactive product not attached, the film is applied to the membrane. One or more bands corresponding to the DNA fragments recognized by the probe can thus be detected.
It is also possible to use the RFLP technique combined with the Southern blotting and/or PCR technique to detect the presence or absence of the rs908832 polymorphism. RFLP makes it possible to compare the
DNAs of various individuals and to investigate whether point mutations causing restriction sites to appear or disappear have occurred. Two DNAs of identical sequence treated with restriction enzymes will give identical fragments, and the Southern blots obtained with these fragments will therefore be identical. On the other hand, if a restriction site has disappeared, or alternatively has appeared, subsequent to a mutation, the fragments will no longer have identical sizes and this will be visible on the autoradiograms. The same is true if a novel restriction site has appeared subsequent to a mutation.
It is also possible to detect the rs908832 polymorphism of the ABCA2Z gene by determining the nucleotide at position 2185 of the transcript encoding the ABCA2 protein.
® ® All the techniques described above are well known tO those skilled in the art. Any other technique which is known and also suitable for detecting the presence or absence of the rs908832 polymorphism can be used. In this respect, mention may, for example, be made of the techniques of Ligase Chain Reaction, Strand
Displacement Amplification, Transcription-based
Amplification, etc. Advantageously, said detection steps are carried out by PCR, RFLP, Southern blotting and/or a combination of these techniques, in accordance with the methods described in the literature (see, for example: Gough et al., Nature, 1990, 347, ©p.773;
Kagimoto et al., J. Biol. Chem., 1990, 265, p. 17209;
Wolf et al., The Lancet, 1990, 336, p. 1452; Hayashi et al., Nucleic Acids Res., 1991, 19, p. 4797; Daly et al., Pharmacogenetics, 1991, 1, p. 33; Spurr et al.,
Methods Enzymol., 1991, 206, p. 149; Armstrong et al.,
The Lancet, 1992, 339, p. 1017; Kurth et al., Am. J. of
Med. Genet., 1993, 48, p. 166; McCann et al., J.
Neurol. Sci., 1997, 153, p. 50; Stroombergen et al.,
Hum. & Exper. Toxicol., 1999, 18, p. 141).
All these methods of detection are particularly useful since they constitute the basis for determining whether an individual may be suffering from Alzheimer’s disease or else exhibits an increased risk of developing
Alzheimer’s disease.
Thus, another subject of the present invention concerns a method for analyzing biological samples taken from an individual, which consists in: a) determining the genotype for the ABCA2 gene of said individual, and b) converting the data obtained in a) in order to give a prognosis for said individual’s risk of developing Alzheimer’s disease and the effectiveness of therapeutic treatments which can be envisioned for this disease.
@® ® According to another aspect, the present invention also relates to the sets, or kits, for the diagnosis or for the prognosis of Alzheimer’s disease in an individual.
Such kits can be in the form of a packaging, compartmentalized so as to accept various containers, such as, for example, vials or tubes. Each one of these containers comprises the various elements required to carry out the detection of the presence or absence of the DNA carrying the rs908832 polymorphism.
Said elements for carrying out the detection reaction(s) are chosen from those described above. They may be, for example: - a pair of primers which hybridize with a defined region of the ABCA2 gene and, optionally, the means necessary for carrying out an amplification reaction, or - oligonucleotide probes, optionally immobilized on a support and comprising a detectable label, and, optionally, the reagents necessary for carrying out a hybridization reaction.
Another subject of the present invention is a method for treating Alzheimer’s disease, which comprises: - at least one step of detection of the presence of the minor allele of the rs908832 polymorphism in an individual, and - the administration of a compound or of a mixture of compounds known for their activity against Alzheimer's disease to an individual exhibiting the minor allele of the rs908832 polymorphism.
Preferably, the disease is early Alzheimer’s disease.
Another subject of the present invention is a method for selecting a compound intended to be administered to an individual exhibiting a disease associated with the minor allele of the rs908832 polymorphism of the ABCA2 gene which comprises:
® ® - 13 - a. at least one step of determination of the presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene in a biological sample from said individual, and i b. the selection of the appropriate compound if said allele is present.
Another subject of the present invention is a method for selecting a compound intended to be administered to an individual exhibiting Alzheimer’s disease, which comprises: a. at least one step of determination of the presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene in a biological sample from said individual; and b. the selection of the appropriate compound if said allele is present.
The present application also relates to the use of a compound or of a mixture of compounds known for their activity against Alzheimer’s disease, for producing a medicinal product for the treatment of an individual suffering from Alzheimer’s disease, in whom the presence of the minor allele of the rs908832 polymorphism has been detected prior to the treatment.
Said compounds known for their activity against
Alzheimer’s disease may, for example, be acetylcholine esterase inhibitors (AchEIs such as Donepezil (Aricept), Galantamine (Reminyl) or Exelon (rivastigmine)), NMDA receptor channel antagonists (such as Memantine (Ebixa)), inhibitors of amyloid peptide production, such as BMS 299897, or future
ABCA2-activity modulators.
® ® The compounds of the combination can be administered orally, parentally, transdermally or rectally, either simultaneously or separately, or in a manner spread out over time.
The compounds are formulated in the form of pharmaceutical compositions containing the combination of one or more compounds as defined above with a pharmaceutically acceptable vehicle.
As solid compositions for oral administration, use may be made of tablets, pills, powders (gelatin capsules, cachets) or granules. In these compositions, the active principles are mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon. These compositions can also comprise substances other than the diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (sugar-coated tablets) or a varnish.
As liquid compositions for oral administration, use may be made of solutions, suspensions, emulsions, syrups and elixirs, which are pharmaceutically acceptable, containing inert diluents such as water, ethanol, glycerol, plant oils or paraffin oil. These compositions can comprise substances other than the diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
The sterile compositions for parental administration can preferably be aqueous or nonaqueous solutions, suspensions or emulsions. As solvent or vehicle, use may be made of water, propylene glycol, a polyethylene glycol, plant oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic solvents. These compositions can also contain adjuvants, in particular wetting agents, isotonicity agents, emulsifiers, dispersing agents and
- 15 =~ ® ® stabilizers. The sterilization can be carried out in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which may be dissolved at the time of use in sterile water or any other injectable sterile medium.
The compositions for rectal administration are suppositories or rectal capsules which contain, besides the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene glycols.
The pharmaceutical compositions containing the combination as defined above generally contain 0.1 to 500 mg of compound.
The doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally from 0.1 to 500 mg of compound per day, orally, for an adult.
In general, the physician will determine the appropriate dosage as a function of age and weight and of all the other factors specific to the individual to be treated.
The present invention also relates to a transgenic animal into the genome of which is inserted at least one exogenous DNA sequence carrying the minor allele of the rs908832 polymorphism such that the function of the
ABCA2 gene is modified.
The term “transgenic animal” is intended to mean any nonhuman animal exhibiting an artificial modification of its genome. The modification of the genome can be the result of an alteration or of a modification of one or more genes by “knock-in” or by “knock-out” (inactivation/modification of genes by homologous
® ® recombination), or the overexpression of the human gene under the control of promoters specific for neuronal cell types (such as ThyI, PDGF or prion) or glial cell types (such as GFAP) in mice. This modification can be due to the action of conventional altering or mutagenic agents or else can be brought about by stable insertion
N of an expression cassette allowing expression of a hybrid gene. In particular, it is for example possible to carry out the procedures according to methods identical or similar to those described in applications
WO 01/02552 or else WO 01/13176.
The modification of the genome can also be the result of an insertion of (a) gene(s) or of a replacement of (a) gene(s) in its (their) wild-type or mutated form.
The modifications are advantageously carried out on reproductive stem cells.
At the current time, modification of the genome using “knock-in” and “knock-out” technology is limited to mice as a model due to the fact that only stem cells (termed “ES” cells) having the ability to colonize the germinal line derived from the mouse embryo are available. When ES cell lines are available for other species, it will be possible for those skilled in the art to readily apply these technologies to these other species in order to generate KO and/or KI models. In addition, approaches based on the use of oligonucleotides (DNA, RNA or hybrids), alone or associated with DNA/RNA-modifying enzymes, can be used to introduce a defined modification/mutation at a given locus in the genome. Even irradiation or chemical mutagens which induce random modifications in the genome can be used if they are combined with an effective set of biological markers (phenotype) and with a high throughput positional cloning procedure.
® ® The most direct approach for modifying the genome of laboratory animals (mice, rats, cows, pigs, sheep, etc.) is, however, the random integration of transgenes by microinjection of linearized DNA into one or two pronuclei of oocytes fertilized at the single-cell stage (preferably, to avoid generating chimeric ) animals, although injection at the stage of two or more cells may also be used). As a general rule, a transgene is made up of two parts: the regulatory elements which impose the spatio-temporal control of expression of the
RNA encoded by the DNA, and said juxtaposed DNA (cDNA or genomic fragment) . These two elements (the regulatory element and the DNA encoding the desired protein) can be homologous or else heterologous to the target genome. The transgenic animals concerned are generally chosen from nonhuman mammals. They may, for example, be murine, i.e. mice, rats and guinea pigs, rabbits, cats, dogs, ovines or else bovines.
Preferably, they are murine animals, rats or rabbits obtained according to conventional transgenesis techniques. Other subjects of the present invention are stem cell lines and cell lines differentiated from these stem cell lines, into the genome of which is inserted at least one exogenous genomic DNA sequence carrying the minor allele of the rs908832 polymorphism.
Succinctly, the production of the transgenic animals, of the stem cell lines and of the differentiated cell lines according to the invention consists of a method using the generation of transgenic animals by insertion, by homologous recombination, of an exogenous genomic DNA encoding the ABCA2 protein into the corresponding gene of the animal (the insertion of the transgene is targeted immediately after the promoter of the animal's gene so as to impose the correct expression profile on the transgene and to prevent expression of the animal's endogenous gene: knocked out) or else by insertion of the specific mutation described in the present invention, corresponding to an
® ® isoform of the human ABCA2 gene, into the animal’s endogenous gene (the modification is brought about by homologous recombination in stem cells: knocked in), or else by overexpression of the ABCA2 gene carrying the minor allele of the rs908832 polymorphism.
In the case of mice, these animals may advantageously be crossed with transgenic mice carrying the human APP gene bearing Alzheimer-type mutations and which develop amyloid plagues. The double transgenic animals thus obtained reproduce the genotype observed in patients suffering from Alzheimer’s disease or at risk. The rs908832 polymorphism genotype of the new born animal thus obtained can be controlled using the techniques already described above, in particular using an amplification reaction (PCR) and/or Southern blotting.
Such transgenic animals are particularly valuable since they provide an advantageous model for understanding
Alzheimer’s disease, which very faithfully reproduces the characteristics of Alzheimer’s disease. By comparison with known models, this model makes it possible in particular to demonstrate compounds which are particularly suitable for the treatment of
Alzheimer’s disease, in particular as described in humans. These compounds may be chemical molecules, peptide or protein molecules, antibodies, chimeric molecules and also antisense DNAs or ribozymes.
The compounds thus demonstrated can be used as a medicinal product, as they stand or in combination with a pharmaceutically acceptable vehicle, in order to obtain a pharmaceutical composition. They may in particular be sterile, isotonic, saline solutions : (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride, etc., or mixtures of such salts), or dry, in particular lyophilized, compositions which, when sterilized water or physiological saline, as appropriate, is added to them
® ® make it possible to constitute injectable solutes. The injections can be carried out stereotaxically, topically, orally, parenterally, intranasally, intravenously, intramuscularly, subcutaneously, intraoccularly, transdermally, etc.
Demonstration of the compounds described above is based on bringing the animal model of the invention into contact, in particular by administration such as for example an injection, with a compound or a mixture of compounds supposed to have an action, and then measuring the effect(s) of the compounds, in particular within the brain in the model, on various biochemical and/or histological changes.
Besides the fact of being able to test, in vivo, therapeutic compounds for preventing, attenuating or curing Alzheimer’s disease, these transgenic animals also make it possible to have an animal model for
Alzheimer’s disease which is of use for screening environmental factors which induce or accelerate the pathogenesis, or else for studying behavior during development of the disease and studying the various biological mechanisms which are involved, for example with the aim of studying new medicinal products or determining the effective amounts of medicinal products and the toxicity. Thus, another subject of the present invention concerns the use of a transgenic animal, of stem cell lines or of differentiating cell lines as defined above, for testing the activity of compounds or of methods intended to prevent and/or treat Alzheimer’s disease. Another subject of the invention concerns a cell extracted from the transgenic animals as described above, and also its use for demonstrating compounds intended for the treatment of Alzheimer’s disease.
The demonstration of compounds described above is based on bringing cells extracted from the animal model of the invention into contact with a compound or a mixture
[ o of compounds supposed to have an action, and then measuring the effect(s) of the compounds on whole cells, in cell homogenates or on a subcellular fraction, on various parameters such as cell death for example.
Besides the above arrangements, the present invention also comprises other characteristics and advantages which will emerge from the examples and figures which follow, and which should be considered to illustrate the invention without limiting the scope thereof.
Example 1: Study of the genotype of the rs908832 polymorphism of the ABCA2 gene in a patient sample
A collection of DNAs derived from patients of Caucasian origin suffering from Alzheimer’s disease and from control individuals was used, after they had given their informed consent.
The frequency of the polymorphisms was determined by genotyping a sample of 47 individuals of a panel marketed by the Coriell Institute (USA).
Ten polymorphisms (including the rs908832 polymorphism) were selected on the basis of their location in the gene and of their frequency in order to be genotyped in the patients suffering from Alzheimer’s disease and the controls.
The genotypes were prepared by the 5’ nuclease assay method (technique for allelic discrimination from
Applied Biosystems, Foster City, USA), and then a Chi2 statistical analysis was carried out by testing the association of each one of these markers with
Alzheimer’s disease (heterogeneity test). For the analysis, groups were distinguished according to the
® o age at which the disease appeared early (before or at 65 years old) or late (after 65 years old)) and its origin (sporadic (first known case) or familial (other cases already known in the same family)).
The results obtained for the rs908832 polymorphism are as follows: - frequency of the minor allele (T) in the patients (440 genotypes): 7.4 - frequency of the minor allele (T) in the controls (519 genotypes): 3.4
The Hardy-Weinberg proportions were verified in the patients and the controls: no significant deviation is observed, which confirms that there is no genotyping error.
Results of the tests carried out in the patients exhibiting an early form of the disease (before or at 65 years old): - 136 sporadic cases vs 272 controls: - heterogeneity test: chi2 (1441) = 22.69 p = 2x10°¢ - allelic test (freq(T) vs freq(C)): chi2 (1441) = 21.27 p = 4x10°° - 104 familial cases vs 272 controls: - heterogeneity test: chi2 (2ddl) = 7.80 p = 0.02 - allelic test (freq (T) vs freqg(C)): chi2 (1ddl) = 7.27 p = 7x1073
The odd ratio was estimated by logistic regression in the 240 patients exhibiting the early form (adjustment with respect to the sex and APOE-€4 status). The result is also significant: OR = 3.97 IC = [2.23 - 7.09].
® ® The values obtained remain significant (threshold fixed at 0.05) even after correction for multiple tests by the Bonferroni method.
These results indicate that the ABCA2 gene is a gene which is important in the etiology of
Alzheimer’s disease.
In terms of risk, this result is of the same order of magnitude as the risk conferred by the apolipoprotein E4, the most commonly known risk factor for Alzheimer’s disease to date.
Example 2: Production of transgenic mice l. Generation of a transgenic mouse expressing the human ABCA2 protein
Mutagenesis of the human ABCA2 protein is carried out using an in vitro mutagenesis system such as Sculptor™ (Amersham, France). The coding region of ABCA2 is subcloned into a cloning vector of the Bluescript type (stratagene) and the mutations are introduced according to the protocol provided by the manufacturer, using oligonucleotides containing the desired mutation. The mutated sequences are to be verified by sequence analysis. 2. Generation and identification of the ABCA2 transgenic mice
To construct the transgene, the genomic DNA encoding
ABCA2 and exhibiting the minor allele of the human rs908832 polymorphism is subcloned into the polylinker of a vector for transgenic expression specific for certain tissues/cell types, such as THYI (Liithi et al.,
J. Neuroscience, 17, pp. 4688-99), PDGF or prion for neuronal types, or GFAP for astrocytic types. A plasmid preparation kit (Qiagen) is used to prepare the supercoiled DNA. For the microinjection, the vector
® ® sequences have to be eliminated by digestion with a defined restriction enzyme, leaving intact the entire transgene and separating it from the needless sequences of the cloning vector. The fragment containing the expression cassette is then purified by agarose gel electrophoresis.
The aliquots intended for the microinjection are dialyzed against a TE buffer (10 mM Tris pH 7.4; 0.1 mM
EDTA) on a floating filter (Millipore; membrane type:
VS; 0.025 um) and then filtered (Spin-X; Costar; polyacetate membrane; 0.22 um). The DNA is diluted to the final concentration of 1-2 ng/ul for the microinjection. The purified fragment is injected into one of the two pronuclei of the fertilized mouse oocytes. The surviving embryos are immediately transplanted into the oviduct of (“pseudopregnant”) adoptive mothers. The presence of the transgene in the newborns is determined either by PCR or by Southern analysis, using specific probes/sequences. By virtue of all these analyses, it is possible to exclude any major rearrangement or deletions of the transgene in the founders and their descendants. 3. Generation of transgenic animals comprising the human ABCA2 protein in their genome
Homologous recombination technology in stem cells is used to introduce the ABCA2 gene exhibiting the minor allele of the human rs908832 polymorphism into the mouse gene, at the desired predefined position. The primers and samples described in the present invention can be readily used to screen isogenic mouse genomic libraries (lambda, BAC, YAC, etc. libraries) in order to isolate and clone the corresponding mouse gene. Said mouse gene 1s characterized in terms of its genomic organization and its sequence using standard techniques known to those skilled in the art (restriction site mapping, sequencing, biocanalytical tools) in order to o @ define the exact site where the human DNA should be inserted to obtain the desired expression profile for the human DNA while at the same time definitively interrupting the expression of the murine gene. Once the exact position has been identified, a standard targeting vector for stem cells (i.e. a vector having markers for selection of the desired events, said markers all being well known to those skilled in the art specialized in the field) is constructed. Rapidly, a selection cassette (gene for resistance to an antibiotic) is placed at the limit of the 3’ and 5° ends of the mouse genomic DNA fragments (2-6 kb) identical to the 3’ and 5’ extensions of the sequence of the murine ABCA2 gene located immediately after the selected site of insertion.
Based on knowledge of the mouse gene, a positive control vector for screening of the recombinant stem cells is generated (the vector reproduces the locus of the murine gene once integration has successfully taken place) in order to optimize and validate the high throughput screening procedure.
The DNA is purified for the targeting experiments in accordance with standard procedures. The targeting vector 1s introduced into the stem cells using standardized electroporation techniques, after which the stem cell clones are subjected to a sequential screening procedure (antibiotics) so as to promote the clones of stem cells carrying the desired recombination. In general, the screening takes approximately 2 weeks. The resistant stem cell clones are screened by PCR and/or Southern.
The clones of stem cells having the desired recombination without any other detectable modification in their genome are developed so as to obtain sufficient cells. Said cells are then injected into 3 and a half-day embryos obtained from a female having
® @ ovulated naturally. The surviving blastocytes (comprising the stem cells) are implanted into a recipient female, which will allow the blastocytes to develop to term and will give birth to newborn young mice made up of cells originating from the host blastocytes and the stem cell clones. This type of ) animal is referred to as a “chimeric animal”.
These chimeres (preferably males since most of the stem cell lines are obtained from male mice) are “matched” with wild-type mice so as to obtain animals which are heterozygous for the modification. Breeding heterozygous animals with one another makes it possible to generate homozygous animals. 4. Generation of transgenic animals comprising the minor allele of the rs908832 polymorphism of the human
ABCA2 gene in their corresponding gene
The murine gene is isolated and characterized in the same way as described above. For this type of modification, it is essential to compare the human gene and the murine gene in order to identify the exact position where the point of mutation found in humans must be introduced into the murine gene. A bioanalysis is essential at this stage. At the end, the targeting vector is developed and assembled in the same way as described above. After successful homologous recombination, nothing more than the desired point of mutation has changed in the coding sequence of the murine gene. Some selection markers can remain in an intron, but they generally have no effect on expression of the gene. If necessary, they can be removed using a second generation of targeting vectors which include recombinase recognition elements. Once the construct has been assembled, the steps are identical to those of the procedure described above.
® @ In general, these ABCA2 transgenic mice will be favorably crossed with transgenic mice expressing the
APP gene carrying the mutations of the familial forms of Alzheimer’s disease in order to promote the deposition of amyloid plaques. 5. Neurchistopathology
Preparation of brain tissue
The mice must be deeply anaesthetized (Pentobarbital: 60 mg/ml/kg i.p., Ketamine: 40 mg/ml/kg i.p.) and then perfused transcardially with physiological saline and then paraformaldehyde (4% in PBS). Next, the brains are removed and then post-fixed in the same fixing solution for 24 hours at 4°C. After fixing, the brains are separated into right and left half-brains and then subjected to the standard protocol for paraffin embedding.
The paraffin-embedded left half-brains of the transgenic and nontransgenic mice, and also blocks of postmortem human brain tissue (frontal cortex) from individuals suffering from Alzheimer’s disease and from a control individual, are sectioned at a thickness of 6 um (serial sections), using a microtome (LEICA RM 2155, France). The tissue blocks corresponding to the right half-brains of the transgenic and nontransgenic mice are sectioned at a thickness of 25 um.
Immunoreactivity for the AB amyloid peptide will be detected as commonly described by those skilled in the art.
Claims (55)
1. A method for the diagnosis or for the prognosis of Alzheimer’s disease in an individual, which comprises at least one step of detection of the presence of a polymorphism of the ABCA2 gene.
2. The method as claimed in claim 1, which comprises at least one step of detection of the presence of the minor allele of a polymorphism of the ABCA2 gene genetically associated with Alzheimer’s disease.
3. The method as claimed in claim 1, which comprises at least one step of detection of the presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene.
4. The method as claimed in claim 1, wherein said detection steps are carried out using biological samples.
5. The method for the diagnosis or for the prognosis of Alzheimer’s disease in an individual as claimed in claim 4, wherein said biological samples are samples containing nucleated cells.
6. The method for the diagnosis or for the prognosis of Alzheimer’s disease in an individual as claimed in claim 4 or 5, wherein said biological samples are blood samples, sperm samples or hair samples.
7. The method for the diagnosis or for the prognosis of Alzheimer’s disease in an individual as claimed in claim 1, wherein said steps of detection of the presence or absence of the DNAS carrying the polymorphism are carried out by techniques of polymerase chain reaction (PCR), of hybridization, of Southern blotting onto membrane, of digestion with nucleases, of restriction fragment length polymorphism
® ® (RFLP) or of direct sequencing, or a combination thereof.
8. The method as claimed in claim 7, which comprises:
a. extracting the DNA of said individual,
b. amplifying said isolated DNA using primers capable of amplifying the sequence corresponding to the rs908832 polymorphism of the ABCA2 gene,
c. determining the presence of at least one of the alleles of the 1rs908832 polymorphism of the ABCA2 gene in the amplified DNA.
9. The method as claimed in claim 8, wherein the amplification step b) comprises a polymerase chain reaction (PCR).
10. The method as claimed in claim 8, wherein the amplified DNA carrying the minor allele of the rs908832 polymorphism is distinguished from the amplified DNA not carrying this allele by the technique using the 5° nuclease activity of DNA polymerase I (TagMan).
11. The method as claimed in claim 8, wherein the amplified DNA carrying the minor allele of the rs908832 polymorphism is distinguished from the amplified DNA not carrying this polymorphism by restriction fragment polymorphism (RFLP) analysis.
12. The method as claimed in claim 11, wherein the restriction fragments have been obtained by digestion of the amplified DNA with a restriction enzyme before migration in agarose gel, Southern blotting onto membrane and hybridization.
® ® 13. A method for detecting the rs908832 polymorphism of the ABCA2 gene, comprising the determination of the nucleotide at position 2185 of the transcript encoding the ABCA2 protein.
14. A method for analyzing biological samples taken . from an individual, wherein:
a. the genotype for the ABCA2 gene is determined, and b. the data obtained are converted in order to give a prognosis for said individual’s risk of developing Alzheimer’s disease and the effectiveness of therapeutic treatments which can be envisioned for this disease.
15. A primer for amplifying the minor allele of the rs908832 polymorphism.
16. The primer as claimed in claim 15, having between approximately 15 and 30 contiguous nucleotides of the sequence SEQ ID No. 3.
17. The primer as claimed in claim 16, which has the sequence SEQ ID No. 6.
18. The primer as claimed in claim 15, having between approximately 15 and 30 contiguous nucleotides of the sequence complementary to SEQ ID No. 3.
19. The primer as claimed in claim 18, which has the sequence SEQ ID No. 7.
20. A probe having between approximately 12 and 17 contiguous nucleotides of the sequence complementary to SEQ ID No. 3.
® ® 21. The probe as claimed in claim 20, which has the sequence SEQ ID No. 8.
22. A probe having between approximately 12 and 17 contiguous nucleotides of the sequence complementary to SEQ ID No. 4.
23. The probe as claimed in claim 22, which has the sequence SEQ ID No. 9.
24. A primer and a probe complementary to the primers and probes as claimed in one of claims 16 to 23.
25. A set, or kit, for the diagnosis or for the prognosis of Alzheimer’s disease, which comprises the various elements required to carry out the detection of the presence or absence of the DNAs carrying the minor allele of the rs908832 polymorphism.
26. The set as claimed in claim 25, which comprises a pair of primers as claimed in one of the claims 15 to
19.
27. A transgenic animal, a stem cell line and a line of cells differentiated from this stem cell line, into the genome of which is inserted at least one exogenous genomic DNA sequence carrying the minor allele of the rs908832 polymorphism of the ABCAZ2 gene.
28. The transgenic animal as claimed in claim 27, which is chosen from nonhuman mammals.
29. A method for obtaining transgenic animals, stem cell lines and lines of cells differentiated from these stem cell lines, as claimed in either of claims 27 and 28, which comprises generating transgenic animals, stem cell lines and lines of cells differentiated from these stem cell lines, comprising the minor allele of the rs908832 polymorphism of the human ABCA2 gene.
® ® - 31 -
30. The use of transgenic animals, of stem cell lines and of lines of cells differentiated from these stem cell lines, as claimed in either of claims 27 and 28, for testing the activity of agents or of methods intended to prevent and/or treat Alzheimer’s disease.
31. A cell extracted from transgenic animals as described in either of claims 27 and 28.
32. The use of a cell as claimed in claim 31, for demonstrating compounds intended for the treatment of Alzheimer’s disease.
33. The use of a compound or of a mixture of compounds known for their activity against Alzheimer’s disease, for producing a medicinal product for the treatment of an individual suffering from Alzheimer’s disease, in whom the presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene has been detected prior to the treatment.
34. The use as claimed in claim 33, wherein the disease is early Alzheimer’s disease.
35. A method for selecting a compound intended to be administered to an individual exhibiting a disease associated with the minor allele of the rs908832 polymorphism of the ABCA2 gene which comprises:
a. at least one step of determination of the presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene in a biological sample from said individual, and b. the selection of the appropriate compound if said allele is present.
SE 32 ®
36. The method as claimed in claim 35, wherein the disease associated with the minor allele of the rs908832 polymorphism is Alzheimer's disease.
37. A method for selecting a compound intended to be administered to an individual exhibiting Alzheimer's disease, which comprises:
a. at least one step of determination of the presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene in a biological sample from said individual; and b. the selection of the appropriate compound if said allele is present. 16 38. A substance or composition for use in a method for treating Alzheimer's disease, said substance or composition comprising a compound or a mixture of compounds known for their activity against Alzheimer's disease, and said method comprising detection of the presence of the minor allele of the rs908832 polymorphism in an individual, and administering said substance or composition to an individual exhibiting the minor allele of the rs908832 polymorphism of the ABCA2 gene.
39. A substance or composition for use in a method of treatment as claimed in claim 38, wherein the disease is early Alzheimer's disease. AMENDED SHEET
40. A method as claimed in any one of claims 1 to 12, substantially as herein described and illustrated.
41. A method as claimed in claim 13, substantially as herein described and illustrated.
42. A method as claimed in claim 14, substantially as herein described and illustrated.
43. A primer as claimed in claim 15, substantially as herein described and illustrated.
44. A probe as claimed in claim 20 or claim 22, substantially as herein described and illustrated.
45. A primer and probe as claimed in claim 24, substantially as herein described and illustrated.
46. A set or kit as claimed in claim 25, substantially as herein described and illustrated.
47. An animal as claimed in claim 27, substantially as herein described and illustrated. AMENDED SHEET
» 48. A method as claimed in claim 29, substantially as herein described and illustrated.
49. Use as claimed in claim 30, substantially as herein described and illustrated.
50. A cell as claimed in claim 31, substantially as herein described and illustrated.
51. Use as claimed in claim 32, substantially as herein described and : illustrated.
52. Use as claimed in claim 33, substantially as herein described and illustrated.
53. A method as claimed in claim 35 or claim 37, substantially as herein described and illustrated.
54. A substance or composition for use in a method of treatment as claimed in claim 38, substantially as herein described and illustrated.
55. A new method for the diagnosis or prognosis of Alzheimer's disease, a new method for detecting a polymorphism, a new method for analyzing biological samples, a new primer, a new probe, a new primer and probe, a new set or kit, a new animal, a new method for obtaining animals, a new use AMENDED SHEET
» of animals as defined in claim 30, a new cell, a new use of a cell as claimed in claim 31, a new use of a compound as defined in claim 33, a new method for selecting a compound, or a substance or composition for a new use in a method of treatment, substantially as herein described.
AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0307501A FR2856409B1 (en) | 2003-06-20 | 2003-06-20 | METHODS OF DETECTING ALZHEIMER'S DISEASE |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200509945B true ZA200509945B (en) | 2007-03-28 |
Family
ID=33484616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200509945A ZA200509945B (en) | 2003-06-20 | 2005-12-07 | Methods for the diagnosis and prognosis of Alzheimer's disease |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1639139B1 (en) |
JP (1) | JP4691491B2 (en) |
KR (1) | KR101170651B1 (en) |
CN (1) | CN1809645B (en) |
AR (1) | AR044492A1 (en) |
AT (1) | ATE518005T1 (en) |
AU (1) | AU2004249919B2 (en) |
BR (1) | BRPI0411658A (en) |
CA (1) | CA2529633C (en) |
CY (1) | CY1111970T1 (en) |
DK (1) | DK1639139T3 (en) |
ES (1) | ES2370491T3 (en) |
FR (1) | FR2856409B1 (en) |
HK (1) | HK1090392A1 (en) |
HR (1) | HRP20110778T1 (en) |
IL (1) | IL172690A0 (en) |
MX (1) | MXPA05012800A (en) |
NO (1) | NO20060257L (en) |
PL (1) | PL1639139T3 (en) |
PT (1) | PT1639139E (en) |
RU (2) | RU2380423C2 (en) |
SI (1) | SI1639139T1 (en) |
TW (1) | TWI352738B (en) |
WO (1) | WO2004113568A2 (en) |
ZA (1) | ZA200509945B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103013989A (en) * | 2011-09-23 | 2013-04-03 | 深圳北京大学香港科技大学医学中心 | Single-nucleotide polymorphisms of cyclin dependent kinase 5 related to senile dementia incidence |
GB201212084D0 (en) * | 2012-07-06 | 2012-08-22 | Randox Lab Ltd | Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment |
CN102768189B (en) * | 2012-07-30 | 2014-11-19 | 黄石 | Method for screening drugs |
CN104313144B (en) * | 2014-10-16 | 2017-02-01 | 卫生部北京医院 | Reagent for detecting susceptibility of Alzheimer's disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5853995A (en) * | 1997-01-07 | 1998-12-29 | Research Development Foundation | Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6 |
CA2383063A1 (en) * | 1999-08-20 | 2001-03-01 | Catriona Wilson | Human abc2 transporter and uses thereof |
AU7699501A (en) * | 2000-07-20 | 2002-02-05 | Cephalon Inc | Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
JP2004147502A (en) * | 2000-07-26 | 2004-05-27 | Banyu Pharmaceut Co Ltd | Human and rat abca2 gene |
WO2002064781A2 (en) * | 2001-02-09 | 2002-08-22 | Active Pass Pharmaceuticals, Inc. | Regulation of amyloid precursor protein expression by modification of abc transporter expression or activity |
WO2002101392A2 (en) * | 2001-06-08 | 2002-12-19 | Xenon Genetics, Inc. | Methods for treating disorders of the nervous and reproductive systems |
-
2003
- 2003-06-20 FR FR0307501A patent/FR2856409B1/en not_active Expired - Fee Related
-
2004
- 2004-06-09 AR ARP040101994A patent/AR044492A1/en active IP Right Grant
- 2004-06-17 JP JP2006516300A patent/JP4691491B2/en not_active Expired - Fee Related
- 2004-06-17 MX MXPA05012800A patent/MXPA05012800A/en active IP Right Grant
- 2004-06-17 RU RU2006101561/13A patent/RU2380423C2/en not_active IP Right Cessation
- 2004-06-17 WO PCT/FR2004/001509 patent/WO2004113568A2/en active Application Filing
- 2004-06-17 CN CN2004800172750A patent/CN1809645B/en not_active Expired - Fee Related
- 2004-06-17 ES ES04767370T patent/ES2370491T3/en not_active Expired - Lifetime
- 2004-06-17 DK DK04767370.2T patent/DK1639139T3/en active
- 2004-06-17 CA CA2529633A patent/CA2529633C/en not_active Expired - Fee Related
- 2004-06-17 SI SI200431759T patent/SI1639139T1/en unknown
- 2004-06-17 PT PT04767370T patent/PT1639139E/en unknown
- 2004-06-17 AU AU2004249919A patent/AU2004249919B2/en not_active Ceased
- 2004-06-17 AT AT04767370T patent/ATE518005T1/en active
- 2004-06-17 EP EP04767370A patent/EP1639139B1/en not_active Expired - Lifetime
- 2004-06-17 PL PL04767370T patent/PL1639139T3/en unknown
- 2004-06-17 RU RU2009104533/10A patent/RU2483108C2/en not_active IP Right Cessation
- 2004-06-17 BR BRPI0411658-5A patent/BRPI0411658A/en not_active IP Right Cessation
- 2004-06-17 KR KR1020057024490A patent/KR101170651B1/en not_active IP Right Cessation
- 2004-06-18 TW TW093117572A patent/TWI352738B/en not_active IP Right Cessation
-
2005
- 2005-12-07 ZA ZA200509945A patent/ZA200509945B/en unknown
- 2005-12-19 IL IL172690A patent/IL172690A0/en not_active IP Right Cessation
-
2006
- 2006-01-18 NO NO20060257A patent/NO20060257L/en not_active Application Discontinuation
- 2006-10-10 HK HK06111103.5A patent/HK1090392A1/en not_active IP Right Cessation
-
2011
- 2011-10-26 HR HR20110778T patent/HRP20110778T1/en unknown
- 2011-10-27 CY CY20111101024T patent/CY1111970T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6902907B1 (en) | Cystic fibrosis gene | |
US20160265052A1 (en) | Gene for Identifying Individuals with Familial Dysautonomia | |
JP5686335B2 (en) | Diagnostic marker and method for amyotrophic lateral sclerosis, model animal that develops amyotrophic lateral sclerosis, and model cell | |
ZA200509945B (en) | Methods for the diagnosis and prognosis of Alzheimer's disease | |
KR20020059347A (en) | Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications | |
EP0970243B1 (en) | Diagnosis and treatment of glaucoma | |
US7803538B2 (en) | Method for detecting Alzheimer's disease | |
AU2009200195A1 (en) | Organic anion transport polypeptide related protein-4 (OATPRP4) gene in | |
ES2349032T3 (en) | POLYMORPHYSMS IN THE HUMAN GENE OF POLYPEPTIDE 2C8 CITOCROMO P450 AND ITS USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS. | |
FR2828212A1 (en) | Diagnosis and prognosis of Parkinson's disease, by detecting simultaneous presence of a CYP2D6-B mutations and deletion of GSTM1, both homozygous | |
US6869768B2 (en) | Association between the acid phosphatase (ACP1) gene and Alzheimer's disease | |
US5830661A (en) | Diagnosis and treatment of glaucoma | |
Ging | Investigating the Role of Modifiers in Trinucleotide Repeat Diseases | |
US20190276891A1 (en) | Gene for identifying individuals with familial dysautonomia |